Cargando…

mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment

Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome, resulting in neutropenia and a risk of myeloid neoplasia. A mutation in a ribosome maturation factor accounts for almost all of the cases. Lymphoid involvement in SDS has not been well characterized. We recently repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Vella, Antonio, D’Aversa, Elisabetta, Api, Martina, Breveglieri, Giulia, Allegri, Marisole, Giacomazzi, Alice, Marinelli Busilacchi, Elena, Fabrizzi, Benedetta, Cestari, Tiziana, Sorio, Claudio, Bedini, Gloria, D’Amico, Giovanna, Bronte, Vincenzo, Poloni, Antonella, Benedetti, Antonio, Bovo, Chiara, Corey, Seth J., Borgatti, Monica, Cipolli, Marco, Bezzerri, Valentino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139896/
https://www.ncbi.nlm.nih.gov/pubmed/32150944
http://dx.doi.org/10.3390/cancers12030597
_version_ 1783518871660003328
author Vella, Antonio
D’Aversa, Elisabetta
Api, Martina
Breveglieri, Giulia
Allegri, Marisole
Giacomazzi, Alice
Marinelli Busilacchi, Elena
Fabrizzi, Benedetta
Cestari, Tiziana
Sorio, Claudio
Bedini, Gloria
D’Amico, Giovanna
Bronte, Vincenzo
Poloni, Antonella
Benedetti, Antonio
Bovo, Chiara
Corey, Seth J.
Borgatti, Monica
Cipolli, Marco
Bezzerri, Valentino
author_facet Vella, Antonio
D’Aversa, Elisabetta
Api, Martina
Breveglieri, Giulia
Allegri, Marisole
Giacomazzi, Alice
Marinelli Busilacchi, Elena
Fabrizzi, Benedetta
Cestari, Tiziana
Sorio, Claudio
Bedini, Gloria
D’Amico, Giovanna
Bronte, Vincenzo
Poloni, Antonella
Benedetti, Antonio
Bovo, Chiara
Corey, Seth J.
Borgatti, Monica
Cipolli, Marco
Bezzerri, Valentino
author_sort Vella, Antonio
collection PubMed
description Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome, resulting in neutropenia and a risk of myeloid neoplasia. A mutation in a ribosome maturation factor accounts for almost all of the cases. Lymphoid involvement in SDS has not been well characterized. We recently reported that lymphocyte subpopulations are reduced in SDS patients. We have also shown that the mTOR-STAT3 pathway is hyper-activated in SDS myeloid cell populations. Here we show that mTOR-STAT3 signaling is markedly upregulated in the lymphoid compartment of SDS patients. Furthermore, our data reveal elevated IL-6 levels in cellular supernatants obtained from lymphoblasts, bone marrow mononuclear and mesenchymal stromal cells, and plasma samples obtained from a cohort of 10 patients. Of note, everolimus-mediated inhibition of mTOR signaling is associated with basal state of phosphorylated STAT3. Finally, inhibition of mTOR-STAT3 pathway activation leads to normalization of IL-6 expression in SDS cells. Altogether, our data strengthen the hypothesis that SDS affects both lymphoid and myeloid blood compartment and suggest everolimus as a potential therapeutic agent to reduce excessive mTOR-STAT3 activation in SDS.
format Online
Article
Text
id pubmed-7139896
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71398962020-04-13 mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment Vella, Antonio D’Aversa, Elisabetta Api, Martina Breveglieri, Giulia Allegri, Marisole Giacomazzi, Alice Marinelli Busilacchi, Elena Fabrizzi, Benedetta Cestari, Tiziana Sorio, Claudio Bedini, Gloria D’Amico, Giovanna Bronte, Vincenzo Poloni, Antonella Benedetti, Antonio Bovo, Chiara Corey, Seth J. Borgatti, Monica Cipolli, Marco Bezzerri, Valentino Cancers (Basel) Article Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome, resulting in neutropenia and a risk of myeloid neoplasia. A mutation in a ribosome maturation factor accounts for almost all of the cases. Lymphoid involvement in SDS has not been well characterized. We recently reported that lymphocyte subpopulations are reduced in SDS patients. We have also shown that the mTOR-STAT3 pathway is hyper-activated in SDS myeloid cell populations. Here we show that mTOR-STAT3 signaling is markedly upregulated in the lymphoid compartment of SDS patients. Furthermore, our data reveal elevated IL-6 levels in cellular supernatants obtained from lymphoblasts, bone marrow mononuclear and mesenchymal stromal cells, and plasma samples obtained from a cohort of 10 patients. Of note, everolimus-mediated inhibition of mTOR signaling is associated with basal state of phosphorylated STAT3. Finally, inhibition of mTOR-STAT3 pathway activation leads to normalization of IL-6 expression in SDS cells. Altogether, our data strengthen the hypothesis that SDS affects both lymphoid and myeloid blood compartment and suggest everolimus as a potential therapeutic agent to reduce excessive mTOR-STAT3 activation in SDS. MDPI 2020-03-05 /pmc/articles/PMC7139896/ /pubmed/32150944 http://dx.doi.org/10.3390/cancers12030597 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vella, Antonio
D’Aversa, Elisabetta
Api, Martina
Breveglieri, Giulia
Allegri, Marisole
Giacomazzi, Alice
Marinelli Busilacchi, Elena
Fabrizzi, Benedetta
Cestari, Tiziana
Sorio, Claudio
Bedini, Gloria
D’Amico, Giovanna
Bronte, Vincenzo
Poloni, Antonella
Benedetti, Antonio
Bovo, Chiara
Corey, Seth J.
Borgatti, Monica
Cipolli, Marco
Bezzerri, Valentino
mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
title mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
title_full mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
title_fullStr mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
title_full_unstemmed mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
title_short mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
title_sort mtor and stat3 pathway hyper-activation is associated with elevated interleukin-6 levels in patients with shwachman-diamond syndrome: further evidence of lymphoid lineage impairment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139896/
https://www.ncbi.nlm.nih.gov/pubmed/32150944
http://dx.doi.org/10.3390/cancers12030597
work_keys_str_mv AT vellaantonio mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT daversaelisabetta mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT apimartina mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT breveglierigiulia mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT allegrimarisole mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT giacomazzialice mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT marinellibusilacchielena mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT fabrizzibenedetta mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT cestaritiziana mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT sorioclaudio mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT bedinigloria mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT damicogiovanna mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT brontevincenzo mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT poloniantonella mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT benedettiantonio mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT bovochiara mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT coreysethj mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT borgattimonica mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT cipollimarco mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment
AT bezzerrivalentino mtorandstat3pathwayhyperactivationisassociatedwithelevatedinterleukin6levelsinpatientswithshwachmandiamondsyndromefurtherevidenceoflymphoidlineageimpairment